TURNING POINT TOWARDS BLOOD BIOMARKER-GUIDED TARGETED THERAPY FOR PRECISION MEDICINE IN ALZHEIMER’S DISEASE

Abstract

Biological markers play an increasingly important role in several contexts-of-use (COU) which go beyond consolidated outcome, such as in screening and diagnostic purposes, and include predictive responses, prognostic information (i.e., the likely outcome of an untreated disease), and pure exploratory data to address unresolved scientific questions and discover novel surrogate endpoints (1).